content_image/166929.jpg
For the year ended 31 March 2014, impairment losses rec- ognised for other intangible assets were ¥53,892 million, and the details of the main items are as follows: 

(i) Impairment losses of ¥40,191 million were mainly recog- nised due to the discontinuation of development activities for IPR&Ds. This includes the discontinuation of develop- ment of ASP2408 (Rheumatoid arthritis), ASP2409 (Prevention of organ transplant rejection), the discontinua- tion of development or clinical studies of non-small cell lung cancer (Adjuvant, combination with MetMAb) of erlotinib (Tarceva), termination of the license agreement with AVEO about tivozanib (renal cell carcinoma, colorec- tal cancer, breast cancer), and the amendment of the license agreement with Basilea about isavconazole (azole antifungal) and others. 

(ii) Impairment losses of ¥11,296 million were recognised due to revising sales projections downwards for DIFICLIR sold in Europe for clostridium difficile infection treatment 

## 18. DeferreD taxes 

The breakdown and movement of deferred tax assets and deferred tax liabilities are as follows: 

For the year ended 31 March 2013 

and other marketing rights as the profitability was lower than originally expected. 

## Significant intangible assets 

Significant intangible assets recognised in the consolidated statements of financial position are mainly composed of the rights related to “Tarceva” resulting from the acquisition of OSI Pharmaceuticals, Inc. in 2010 and ones related to the acquired research and development project of ASP1517/yM311 through the license agreement with FibroGen, Inc. The carrying amounts of those intangible assets as of 31 March 2014 were ¥96,108 million and ¥50,565 million (¥120,905 million and ¥49,343 million as of 31 March 2013), respectively. The remaining amortisation period of intangible assets associated with the marketed products is mainly 5 to 6 years, and the intangible assets not yet being amortised are tested for impairment annually. 

<img src='content_image/166929.jpg'>

